coronary artery disease region linked MFGE8 regulatory lncRNAGenealiases: []
Q-omics provides the consensus-scored CARMAL profile across patient tissues and cancer cell-line models. CARMAL expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, CARMAL is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, CARMAL RNA expression shows 10,886 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight BLCA, HNSC, and TGCT as cancer lineages where CARMAL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CARMAL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CARMAL survival associations across molecular data types. CARMAL RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CARMAL RNA expression–survival associations across cancer types. High CARMAL expression shows unfavorable associations in BLCA, KIRP, MESO, COAD, HNSC and LIHC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for CARMAL RNA expression.
This table summarizes CARMAL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CARMAL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CARMAL shows lower tumor expression in KIRC, UCEC, THCA and KICH and higher tumor expression in HNSC and READ. The HNSC box plot shows higher CARMAL RNA expression in tumor versus normal tissue (log2 FC = +0.392, t-test p = .006).
This table shows molecular features associated with CARMAL in patient tissues and cancer cell lines. In patient samples, CARMAL shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
